AIM ImmunoTech Inc

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AIM ImmunoTech reports promising clinical progress and financial stability

AIM ImmunoTech demonstrated strong clinical progress and financial stability, positioning the company well for future growth and potential partnerships.
While facing regulatory and operational challenges, the company's focus on expanding Ampligen's therapeutic applications and medical expertise presents significant opportunities for advancement.
Investors should monitor AIM ImmunoTech's continued progress in clinical trials and regulatory interactions, as positive outcomes could drive value creation and market expansion.

AIM ImmunoTech reports positive clinical progress and solid financial standing

AIM ImmunoTech's Q2 2024 Earnings Call highlighted significant progress in clinical trials for Ampligen, particularly in oncology indications.
Financially, the company maintains a solid cash position and continues to manage expenses to support ongoing operations and future milestones.
While facing challenges in trial design and cost management, AIM ImmunoTech remains well-positioned to capitalize on opportunities for growth and partnership.

AIM ImmunoTech advances Ampligen with positive clinical data amid challenges

AIM ImmunoTech's Q3 showcased progress in Ampligen's development, with promising data supporting its therapeutic potential. While facing financial challenges, the company is focused on leveraging opportunities for collaborations and commercialization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OCALA, Fla., Oct. 06, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today released detailed safety data from a Phase 1 clinical study which supports the company's belief that its drug Ampligen has significant potential as an intranasal therapeutic for COVID-19.

AIM ImmunoTech Publishes Phase 1 Clinical Study Data Supporting the Safety of Ampligen as an Intranasal Therapy

AIM ImmunoTech Inc announced that it has finalized the protocol for a planned Phase 2 study of Ampligen as a therapy for locally advanced or metastatic late-stage pancreatic cancer. The company expects to submit both an Investigational New Drug application (IND) and a request for Fast Track status with the US Food and Drug Administration (FDA) by no later than October 18.

AIM ImmunoTech finalizes protocol for planned Phase 2 study of Ampligen in patients with pancreatic cancer

Finalizes and reports Phase 2 study protocol

AIM ImmunoTech Provides Clinical Updates on Planned Phase 2 Study of Ampligen in Patients with Locally Advanced or Metastatic Late-Stage Pancreatic Cancer

Lead drug Ampligen in clinical trials to address both chronic fatigue syndrome and to treat multiple cancers Clinical trial also widened to include cancer patients suffering from long-term effects of coronavirus Positive results from a pancreatic cancer Early Access Program (EAP) evaluating Ampligen in the Netherlands. What AIM ImmunoTech does: AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) is an immuno-pharma company headquartered in Ocala, Florida which is focused on the research and development of therapeutics to treat multiple types of cancers, as well as immune-deficiency disorders.

AIM ImmunoTech developing immuno-therapeutics to treat cancer and fight coronavirus

AIM ImmunoTech Inc (NYSE: AIM) has signed a Clinical Trial Agreement with hVIVO for Phase 2a Human Challenge Trial (HCT) for intranasal Ampligen as prophylaxis against respiratory viruses. The HCT will test Ampligen as a potential intranasal prophylactic using a human rhinovirus (HRV-16, a common cold virus) and influenza A virus (H3N2).

AIM ImmunoTech Recruits hVIVO For Ampligen Trial For Prophylaxis Use Against Respiratory Viruses

AIM ImmunoTech Inc. said it has signed a signed clinical trial agreement for a Phase 2a Human Challenge Trial (HCT) with hVIVO for a Phase 2a Human Challenge Trial (HCT) to test the company's flagship drug Ampligen as a potential intranasal prophylactic using a human rhinovirus (HRV-16, a common cold virus) and influenza A virus (H3N2).

AIM ImmunoTech inks clinical trial agreement for a Phase 2a Human Challenge Trial of Ampligen as an intranasal prophylaxis against respiratory viruses

The governing ethics committee and regulatory agency have met on the study protocol and plan to issue their response in Q4; AIM anticipates that the trial will commence shortly thereafter The governing ethics committee and regulatory agency have met on the study protocol and plan to issue their response in Q4; AIM anticipates that the trial will commence shortly thereafter

AIM ImmunoTech Announces Clinical Trial Agreement for a Phase 2a Human Challenge Trial of Ampligen as a Potential Intranasal Prophylaxis Against Respiratory Viruses

AIM ImmunoTech Inc (NYSE: AIM) submitted a Pre-Investigational New Drug Application (Pre-IND) to the FDA for COVID-19 trials with Ampligen. The application is for two separate Phase 2 clinical studies to study the potential of Ampligen as both an infusion and an intranasal therapy for early-onset COVID-19.

AIM ImmunoTech Plans To Evaluate Two Forms Of Ampligen In Early-COVID-19 Disease

AIM ImmunoTech Inc announced it had submitted a pre-investigational New Drug application (pre-IND) to the US Food and Drug Administration (FDA) for two separate Phase 2 clinical studies to study Ampligen as both an infusion and an intranasal therapy for early-onset coronavirus (COVID-19). "With Ampligen's recently established intranasal safety profile, and the preliminary results from these trials, we may be able to show that Ampligen not only has an early-onset therapeutic effect against a broad spectrum of respiratory viruses, but also may provide a boost to post-infection immunity that will confer cross-protection against viral variants,"  AIM CEO Thomas K.

AIM ImmunoTech submits Pre-IND application to FDA for Phase 2 trials of Ampligen as potential therapeutic for early-onset coronavirus

AIM Has Reached Multiple Major Milestones Demonstrating Strong Progress in Developing its COVID-19 Portfolio AIM Has Reached Multiple Major Milestones Demonstrating Strong Progress in Developing its COVID-19 Portfolio

AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Studies of Ampligen as a Potential Early-Onset Therapeutic for COVID-19

AIM ImmunoTech Inc said it has submitted a provisional patent application for Ampligen as a potential early-onset intranasal therapy. This therapeutic use is designed to enhance and expand infection-induced immunity, epitope spreading, cross-reactivity and cross-protection in patients exposed to a wide range of RNA respiratory viruses, such as influenza, Rhinoviruses and SARS-CoV-2, which causes the coronavirus (COVID-19).

AIM ImmunoTech files provisional patent for Ampligen as a potential early-onset intranasal therapy

OCALA, Fla., Sept. 27, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced the filing of a provisional patent application for Ampligen as a potential early-onset intranasal therapy designed to enhance and expand infection-induced immunity, epitope spreading, cross-reactivity and cross-protection in patients exposed to a wide range of RNA respiratory viruses, such as influenza, Rhinoviruses and SARS-CoV-2, which causes the disease COVID-19.

AIM ImmunoTech Files Provisional Patent Application for Ampligen as an Early-Onset Intranasal Therapy that May Also Confer Enhanced Immunity to a Wide Range of Respiratory Viruses

AIM ImmunoTech Inc (NYSE: AIM) has announced positive progress with the FDA meeting request concerning a Phase 2 study of Ampligen for Post-COVID-19 Cognitive Dysfunction (PCCD).  The meeting request has been deemed sufficient for transfer to the FDA's Division of Neurology by the FDA's COVID Scientific Technical Triage Team.

AIM ImmunoTech Receives Positive FDA Response For Ampligen Trial In PCCD Patients

AIM ImmunoTech Inc has progressed a step further in its bid to get Ampligen into a clinical trial to test it as an infusion therapy for Post-COVID-19 Cognitive Dysfunction (PCCD) - a new and serious coronavirus-induced disease for which there is currently no treatment. The FDA has deemed a meeting request sufficient for transfer now to the regulator's Division of Neurology by the FDA's Covid scientific technical triage team.

AIM ImmunoTech advances bid to study Ampligen as therapy for Post-COVID-19 Cognitive Dysfunction

OCALA, Fla., Sept. 21, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced positive progress with the company's meeting request to the U.S. Food and Drug Administration (FDA) concerning a Phase 2 clinical study of Ampligen as an infusion therapy for Post-COVID-19 Cognitive Dysfunction (PCCD). The meeting request has been deemed sufficient for transfer to the FDA's Division of Neurology by the FDA's Covid Scientific Technical Triage Team.

AIM ImmunoTech Announces Positive Progress on Requested FDA Meeting for Proposed Ampligen Clinical Trial in Post-COVID-19 Cognitive Dysfunction

AIM ImmunoTech Inc. provided a status update on its Phase 2a Human Challenge Trial (HCT) to test the company's flagship drug Ampligen as a potential intranasal prophylactic therapy using a human rhinovirus (HRV-16), which is a common cold virus, and influenza A virus (H3N2).

AIM ImmunoTech offers a status update on its pending Phase 2a Human Challenge Trial using its flagship drug Ampligen

OCALA, Fla., Sept. 20, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today provided a status update on its Phase 2a Human Challenge Trial (HCT) to test the company's drug Ampligen as a potential intranasal prophylactic therapy using a human rhinovirus (HRV-16, a common cold virus) and influenza A virus (H3N2). The proposed protocol for the AIM-sponsored study was submitted to the Oxford Research Ethics Committee (REC)/Medicines and Healthcare Regulatory Agency (MHRA) on September 10, 2021. A meeting is scheduled to review the study on September 24, and the response is expected by mid November.

AIM ImmunoTech Provides an Update on Its Pending Phase 2a Human Challenge Trial Using its Drug Ampligen

AIM ImmunoTech Inc (NYSE: AIM) has submitted a Pre-Investigational New Drug application (Pre-IND) to the FDA for a Phase 2 study of Ampligen as a potential infusion therapy for Post-COVID-19 Cognitive Dysfunction (PCCD). The trial will evaluate the efficacy and safety of Ampligen in patients experiencing PCCD.

AIM ImmunoTech To Test Ampligen In Post-COVID-19 Cognitive Dysfunction

AIM ImmunoTech Inc. said it has submitted a pre-Investigational New Drug (Pre-IND) application to the US Food and Drug Administration (FDA) for a Phase 2 clinical study of Ampligen as a potential infusion therapy for post-coronavirus (COVID-19) Cognitive Dysfunction (PCCD).

AIM ImmunoTech submits pre-Investigational New Drug application to the US FDA for a Phase 2 clinical study of Ampligen as a potential infusion therapy for post-COVID-19 Cognitive Dysfunction

OCALA, Fla., Sept. 08, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that is has submitted a Pre-Investigational New Drug application (Pre-IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2 clinical study of Ampligen as a potential infusion therapy for Post-COVID-19 Cognitive Dysfunction (PCCD).

AIM ImmunoTech Submits Pre-IND Application to the FDA for Phase 2 Clinical Study of Ampligen as a Potential Infusion Therapy for Post-COVID-19 Cognitive Dysfunction

AIM ImmunoTech Inc has announced a new provisional patent application for its flagship drug candidate Ampligen as both an intranasal and an intravenous therapy for what the company describes as Post-COVID-19 Cognitive Dysfunction (PCCD). The Ocala, Florida-based immuno-pharma company has been working steadily to expand its coronavirus (COVID-19) patent portfolio.

AIM ImmunoTech files provisional patent application for use of Ampligen in Post-COVID-19 Cognitive Dysfunction

AIM ImmunoTech Inc (NYSE:AIM) posted second-quarter results that demonstrated that it is in a strong financial position with $57.3 million to press ahead with clinical trials and execute on its corporate strategy. For the period ended June 30, 2021, the Ocala, Florida-based immuno-pharma company had cash, equivalents and marketable securities of $57.3 million, compared to $54.4 million as of December 31, 2020.

AIM ImmunoTech is well positioned with $57.3M to advance clinical trials of Ampligen as cancer, coronavirus treatment

AIM ImmunoTech Inc posted second-quarter results that demonstrated that it is in a strong financial position with $57.3 million to press ahead with clinical trials and execute on its corporate strategy. For the period ended June 30, 2021, the Ocala, Florida-based immuno-pharma company had cash, equivalents and marketable securities of $57.3 million, compared to $54.4 million as of December 31, 2020.

AIM ImmunoTech is well positioned with $57.3M to execute on its corporate strategy and advance clinical trials

OCALA, Fla., Aug. 17, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) announces financial results for the second quarter ended June 30, 2021 and provides a business update.

AIM ImmunoTech Provides Second Quarter 2021 Business Update

BioFlorida is the State's Leading Life Sciences Industry Association BioFlorida is the State's Leading Life Sciences Industry Association

News for AIM ImmunoTech Inc Stock (AIM)